塞来昔布抑制LPS诱导的小鼠根尖周骨吸收
塞来昔布阻止根尖周骨吸收并减少破骨细胞形成,吲哚美辛7天加重骨吸收、14天无效;塞来昔布调节骨吸收相关基因表达优于吲哚美辛。
要点
- 塞来昔布7天和14天均阻止LPS诱导的根尖周骨吸收(P<0.0001)。
- 塞来昔布减少根尖周炎破骨细胞形成(7天P<0.0001,14天P=0.026)。
- 吲哚美辛7天加重骨吸收(P<0.0001),14天无影响(P=0.8488)。
核心结论
- 选择性COX-2抑制剂塞来昔布通过减少破骨信号和活性抑制LPS诱导的小鼠根尖周骨吸收,效果优于非选择性抑制剂吲哚美辛。
研究设计与样本
- 动物系统给予塞来昔布(15 mg kg-1)或吲哚美辛(5 mg kg-1)7天或14天,进行组织病理学、TRAP、免疫组化和qRT-PCR分析。
主要发现
- 塞来昔布7天和14天阻止根尖周骨吸收(P<0.0001);吲哚美辛7天加重骨吸收(P<0.0001),14天无影响(P=0.8488)。
- 塞来昔布减少破骨细胞形成(7天P<0.0001,14天P=0.026)。
- 7天时塞来昔布和吲哚美辛均抑制组织蛋白酶K mRNA表达(P=0.0005和P=0.016),不改变TRAP、MMP-9和降钙素受体基因表达。
- 14天时塞来昔布抑制MMP-9(P<0.0001)和降钙素受体(P=0.004)mRNA表达;吲哚美辛对MMP-9(P=0.216)和降钙素受体(P=0.971)无影响,但显著增强组织蛋白酶K基因表达(P=0.001)。
临床怎么用
- 动物实验提示选择性COX-2抑制剂塞来昔布可能有助于控制根尖周炎骨破坏,但尚未在人体验证,临床决策需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To evaluate the efficacy of selective and nonselective inhibitors of cyclooxygenase-2 enzymes in the treatment of experimental apical periodontitis induced by bacterial lipopolysaccharide (LPS) in vivo in a mouse model. METHODOLOGY: Thirty-six C57BL/6 mice were used. After access cavity preparation, a solution containing E. coli LPS (1.0 µg µL-1 ) was inoculated into the root canals of the mandibular and maxillary right first molars (n = 72) After 30 days, apical periodontitis was established and the animals were systemically treated with celecoxib, a selective COX-2 inhibitor (15 mg kg-1 ), or indomethacin, a nonselective COX-2 inhibitor (5 mg kg-1 ), for 7 and 14 days. Blocks containing teeth and bone were removed for histopathological and histometric analyses (haematoxylin and eosin), evaluation of osteoclasts numbers (tartrate-resistant acid phosphatase enzyme - TRAP) and immunohistochemistry for RANK, RANKL and OPG. Gene expression was performed using reverse transcription and real-time polymerase chain reaction (qRT-PCR) for RANK, RANKL, OPG, TRAP, MMP-9, cathepsin K and calcitonin receptor. Histopathological, histometric, TRAP, immunohistochemistry and qRT-PCR data were evaluated using Kruskal-Wallis followed by Dunn's test (α = 0.05). RESULTS: Systemic administration of celecoxib for 7 and 14 days prevented periapical bone resorption (P < 0.0001), differently from indomethacin that exacerbated bone resorption at 7 days (P < 0.0001) or exerted no effect at 14 days (P = 0.8488). Celecoxib treatment reduced osteoclast formation in apical periodontitis, regardless of the period of treatment (P < 0.0001 for 7 days and P = 0.026 for 14 days). Administration of celecoxib or indomethacin differentially modulated the expression of genes involved in bone resorption. At 7 days, celecoxib and indomethacin treatment significantly inhibited expression of mRNA for cathepsin K (P = 0.0005 and P = 0.016, respectively) without changing TRAP, MMP-9 and calcitonin receptor gene expression. At 14 days, celecoxib significantly inhibited expression of mRNA for MMP-9 (P < 0.0001) and calcitonin receptor (P = 0.004), whilst indomethacin exerted no effect on MMP-9 (P = 0.216) and calcitonin receptor (P = 0.971) but significantly augmented cathepsin K gene expression (P = 0.001). CONCLUSIONS: The selective COX-2 inhibitor celecoxib reduced osteoclastogenic signalling and activity that dampened bone resorption in LPS-induced apical periodontitis in mice, with greater efficacy than the nonselective inhibitor indomethacin.
引用
- Petean IBF, Almeida-Junior LA, Arnez MFM, et al. Celecoxib treatment dampens LPS-induced periapical bone resorption in a mouse model. Int Endod J. 2021. PMID: 33403674. doi:10.1111/iej.13472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。